Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | ADK | P55263 | 1/20 | 0.51 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27471278 | 0.81 | TDP1 (0.49) | MAPTRAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL76309 | 0.80 | NPC1 (0.55) | MAPTRAB9AMEN1HTTKMT2A | |
| SCHEMBL16777437 | 0.79 | NISCH (0.72) | MEN1KMT2AMTORADKNISCH | |
| SCHEMBL6661337 | 0.77 | PTGS2 (0.53) | MAPTRAB9ASMN1; SMN2KMT2AMTOR | |
| 2-Phenylimidazole SCHEMBL28960135 | 0.76 | NISCH (0.72) | MAPTRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18024778 | 0.76 | MAPT (0.61) | MAPTRAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL6738366 | 0.75 | TSHR (0.76) | MAPTRAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL5249670 | 0.75 | MAPT (0.56) | MAPTRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4331798 | 0.75 | MAPT (0.54) | MAPTRAB9ASMN1; SMN2MEN1HTT | |
| SCHEMBL8539529 | 0.75 | GPR35 (0.49) | MAPTRAB9ASMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105738-A | Preparation method of novel anionic demulsifier for cutting fluid wastewater treatment | 苏州顿莱环保科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-101863894-B | Tanshinone II A derivative and preparation method and application thereof | UNIV GUANGDONG PHARM | 2012-07-18 | — | — | CN | claimed |
| CN-101863894-A | Tanshinone II A derivative and preparation method and application thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY | 2010-10-20 | — | — | CN | claimed |
| CN-101735217-A | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2010-06-16 | — | — | CN | claimed |
| CN-1529597-A | Imidazo (1,2-A)_pyridine derivatives as mGLUR5 antagonists | - | 2004-09-15 | — | — | CN | claimed |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| WO-2024262911-A1 | NOVEL PYRAZOLO PYRIMIDINE-BASED COMPOUND AND USE THEREOF | 주식회사 에이조스바이오 | 2024-12-26 | — | — | WO | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-118105738-A | Preparation method of novel anionic demulsifier for cutting fluid wastewater treatment | 苏州顿莱环保科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-116283668-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-0393721-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0209012-A2 | High contrast photographic elements exhibiting reduced pepper fog | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-01-21 | — | — | EP | disclosed |
| EP-0209011-A2 | High contrast photographic elements exhibiting stabilized sensitivity | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-01-21 | — | — | EP | disclosed |
| EP-0209010-A2 | High contrast photographic elements exhibiting reduced stress sensitivity | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-01-21 | — | — | EP | disclosed |
| EP-0132165-A1 | Adsorbable alkynyl substituted heterocyclic quaternary ammonium salts and applications thereof to silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-23 | — | — | EP | disclosed |
| EP-0130856-A2 | Radiation sensitive silver halide emulsion containing substituted arylhydrazides | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0126000-A2 | Adsorbable arylhydrazides and applications thereof to silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1984-11-21 | — | — | EP | disclosed |
| EP-0023260-B1 | 5-AMINO-BENZIMIDAZOL-2-ONE HYDRATE, PROCESS FOR ITS PREPARATION AND ITS APPLICATION AS PRECURSOR FOR DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | MAPT 2523/4885RAB9A 857/4885SMN1; SMN2 3528/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | MAPT 4671/4885RAB9A 3771/4885SMN1; SMN2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.